Method for treating pervasive development disorders
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Abstract
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
Claims11
A method of selecting an individual with a Pervasive Development Disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:
- a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry;
- b. identifying a patient to be treated as having a subnormal level of chymotrypsin;
- and
- c. selecting the individual for treatment with a pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal.
A method of selecting an individual with a Pervasive Development Disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:
- a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry;
- b. selecting the individual for treatment with the pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal;
- and
- c. administering the pharmaceutical composition comprising one or more digestive enzymes if the individual is selected for treatment.
Dependencies are inferred from the claim text.